Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The European Commission has approved leriglitazone (NEZGLYAL®) as the first pharmacological treatment for cerebral adrenoleukodystrophy (cALD), a rare and rapidly fatal brain disease in young boys. The oral, once-daily therapy targets early-stage patients aged 2–12 before irreversible neurological damage sets in. Germany is set to be the first launch market by year's end.
For the first time, boys diagnosed with cerebral adrenoleukodystrophy (cALD) have a medicine to fight back with. The European Commission has granted marketing authorization for leriglitazone (NEZGLYAL®), developed by Minoryx Therapeutics and commercialized by Neuraxpharm, making it the first approved pharmacological treatment for cALD in the EU. The approval covers male patients aged 2–12 with early-stage (Gadolinium-negative) brain lesions and is valid across all 27 EU member states plus Norway, Iceland, and Liechtenstein.
cALD is an aggressive, demyelinating brain disease that can lead to severe neurological decline and death within 3–4 years of onset. Until now, the only intervention was hematopoietic stem cell transplantation — invasive, donor-dependent, and only viable within a narrow window. Leriglitazone is an oral, brain-penetrating PPAR gamma agonist that offers a non-invasive, disease-modifying option for early intervention, based on Phase 2/3 NEXUS1 trial data and real-world compassionate use evidence.
Key Takeaways:
Why it matters: cALD strikes fast and leaves little room for error — neurodegeneration is irreversible once it begins. Having an oral, early-intervention option could fundamentally change outcomes for affected children and their families.
